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INTRODUCTION
In the initial proposal, two hypotheses were proposed for the development of fusion proteins designed to target erbB-2 bearing tumors and provide the costimulatory signal to anti-tumor T cells. One of the hypotheses proposed the development of bispecific scFv incorporating anti-CD28 scFv. In the last annual report we described the isolation and characterization of scFv specific for the T cell costimulatory receptor CD28 from a phage library. Unfortunately, these scFv failed to localize to CD28 bearing cells and thus
were not utilized for development of bispecific scFv.
Because previous experiments had shown that the simple provision of B7 molecules to tumor cells by transfection could result in T cell activation and induce an antitumor T cell response, it was thought that incorporation of the extracellular domain of the B7 molecule into a fusion protein would be adequate, but perhaps not superior to anti-CD28 scFv, for costimulating T cells. Therefore, to determine whether provision of T cell costimulatory molecules to tumors by antibody based targeting was a viable alternative to tumor transfection, a fusion protein was proposed for development which incorporates the extracellular domain of the T cell costimulatoiy molecule, human B7.2 (hB7.2), separated by a flexible linker from an anti-erbB-2 scFv, C6ML3-9.B I (B 1).
BODY OF REPORT

Results
As a means of providing B7 to tumor cells for the activation of tLlOr specific T cells, a chimeric fusion protein was engineered and produced which can target erbB-2 expressing tumors and provide costimulation to T cells. The resulting fusion protein, hB7.2/B1, incorporated a high affinity scFv, C6ML3-B1, specific for erbB-2 (KI = 120pM) and the extracellular domain of the CD28 ligand, human B7.2, separated by a polyglycine and serine linker.
In last year's report, the hB7.2/B1 chimeric fusion protein produced in Pichia pastoris, was shown to bind to both recombinant and cell surface tumor marker erbB-2 and to T cell counter receptor. HB7.2/B 1 retained an extremely high affinity for erbB -2 showing a Kd of 580pM as compared to 120pM for B 1 scFv (1) .
For the hB7.2/B 1 fusion protein to function as envisioned, it not only has to bind to both erbB-2 bearing tumor cells and to CD28 on T cells but also must provide an effective costimulatory signal to T cells for their activation to occur. To determine whether the hB7. and still effectively costimulate T cells, an alternative assay format was employed. In these assays, CHO-erbB-2 transfectants were preincubated with hB7.2/B I for I hour and then added to Jurkat cells instead of latex beads and assays carried out in an identical manner as described above. CHO cells transfected with human B7.2 were used as a positive control.
In all cases, PMA and ionomycin were used at 1 ng/ml and 1 uM, respectively, to augment the signal. The combination of CHO-erbB-2 plus fusion protein induced an IL-2 response over four times that of CHO-c-erbB-2 alone and approximately two-thirds that of the positive control CHO-hB7.2 ( Figure 3.2) . In addition, the IL-2 produces by Jurkat T cells could be tittered over a range of hB7.2/B I concentrations.
Conclusions
As a means of providing B7 to tumor cells for the activation of tumor specific T cells, a chimeric fusion protein was engineered and produced which can target erbB-2 expressing tumors and provide costimulation to T cells. The resulting fusion protein, hB7.2/B1, incorporated a high affinity scFv, C6ML3-B1, specific for erbB-2 (K, -120pM) and the extracellular domain of the CD28 ligand, human B7.2, separated by a polyglycine and serine linker.
For the proposed fusion protein to function as envisioned, an important assumption was made. If each half of the chimeric molecule is available for binding, and the orientation of the molecule is appropriate for simultaneous binding to erbB-2 on tumor cells and to CD28 on T cells, then the fusion protein should be able to induce activation and proliferation of T cells with similar benefits as were seen with B7 transfected tumor cells (2) (3) (4) (5) (6) (7) (8) . The orientation of the fusion protein, that is whether the T cell costimulatory molecule is at the N-terminus or the C-terminus, was not originally considered to be of primary importance. Initially, a fusion protein was constructed with hB7.2 at the Cterminus of the molecule, however binding experiments with the molecule in this orientation showed a lack of functionality of hB7.2. Another group's work supported this observation. Challita-Eid et al. showed that hB7.1 does not retain native binding characteristics when incorporated into a fusion protein at the C-terminus (9) . Subsequent construction of the chimeric molecule with hB7.2 at the N-terminus resulted in a more successful molecule.
The hB7.2/B 1 chimeric fusion protein produced in Pichia pastoris, was shown to bind to both recombinant and cell surface tumor marker erbB-2 and to T cell counter receptor. HB7.2/B 1 retained an extremely high affinity for erbB-2 showing a K,, of 58OpM as compared to 120pM for BL scFv (1). When hB7.2/B1 was either coated on latex beads or bound to CHO cells transfected with erbB-2, the CD28 binding entity was available to bind T cells and provided costimulation resulting in increased IL-2 production by T cells over control. Therefore, both components of the hB7.2/B I chimeric fusion protein are independently functional and, in addition, hB7.2/B I can bind both counter receptors simultaneously. The hB7.2 component is also able to provide the costimulatory signal to T cells resulting in increased activation. Therefore, our chimeric fusion protein appears to function as envisioned and may be suitable for further in vivo testing.
There are theoretical advantages to activating T cells via costimulatory molecules as compared to anti-CD3 or other conjugates. The three main advantages can be summed Lip as increased specificity, increased range of targets, and longevity of the therapeutic effect. Firstly, T cell activation via costimulatory molecules is antigen specific; the non-tumor killing associated with either CD3 crosslinking, general cytokine therapy, or inlmunotoxil or radioisotope conjugates would be prevented. For example, in anti-tumor therapy using an anti-erbB-2 antibody coupled to CD3, all cells expressing erbB-2 would be targeted for destruction, whereas only those cells displaying immunogenic peptides in the context of MHC molecules should be targeted when using hB7.2/B 1. In addition, the severe toxicity associated with the use of immunotoxins or radioisotope antibody conjugates would be avoided. Secondly, tumor cells need not express erbB-2 to be targeted. Provided that immunogenic peptides displayed by MHC molecules are common between erbB-2 expressers and non-expressers, once a response is generated against a particular antigen, T cells should respond to that antigen regardless of the presence of the erbB-2 marker (5). One way to provide B7 to tumor cells would be to couple an anti-tumor antibody either directly to B7 or to an antibody to the B7 counterreceptor on T cells, CD28. To this end, a fusion protein has been developed which incorporates a single chain antibody fragment (scFv) to c-erbB-2 (Her2/neu), an oncogene product overexpressed by 30-50% of breast carcinomas, and the extracellular domain of B7-1 (CD80). Experiments are currently underway to determine if the fusion protein can bind to c-erbB-2 and CD28, and also to measure its ability to activate T-cells. To explore whether this fusion protein is effective il vivo, it will subsequently be tested for its ability to elicit an anti-tumor response to P8 15 mastocytomas in a mouse system.
In addition, single chain antibody fragments are currently being selected, using a phage display scFv library, which are specific for the T cell costimulatory receptor molecule CD28. Anti-CD28 scFv with a range of affinities will be isolated and the role of affinity and differential binding to T cell costimulatory receptors will be determined to identify their importance in the biology of T cell activation. Since the affinity of B7 for CD28 has been estimated at 4uM, a higher affinity interaction to signal T cells through CD28 may be more advantageous. Anti-CD28 scFv with preferential binding to CD28 versus CTLA-4 may be more effective at T cell costimulation since CTLA-4 is thought to down-regulate T cell responses. Anti-CD28 scFv also can be used with anti-c-erbB-2 scFv to make bispecific antibodies for tumor therapy that may be more efficacious than fusion proteins utilizing B7. To determine whether provision of T cell costimulatory molecules to tumors by antibody based targeting was a viable alternative to tumor transfection, a fusion protein was developed which incorporates an anti-erbB-2 scFv, C6ML3-9.B 1 (B 1), and the T cell costimulatory molecule, human B7.2 (hB7.2). The fusion protein proposed would be entirely human in sequence, would bind to erbB-2 expressing breast tumor cells with high affinity, and should be able to costimulate T cells by signaling through CD28.
MATERIALS AND METHODS
Antibodies and Recombinant Proteins
Antibodies used include anti-human B7. hours, the cells were removed by centrifugation and a protease inhibitor cocktail (Sigma, #P2714) was added to the supernatent to reduce proteolysis of the fusion protein.
For purification, medium containing the secreted fusion protein was concentrated and buffer exchanged by tangential flow in a Centramate system using a 30kD filter cassette Post-translational modification was analyzed by treatment with PNGase. Fusion protein was denatured by 10 minutes at 100'C and incubated with PNGase overnight at 37°C. Both untreated and deglycosylated fusion protein was analyzed by SDS-PAGE and western blotting using anti-C6.5 polyclonal sera.
Recombinant Antigen Binding Assays
Recombinant antigen binding ELISA were performed with 10ug/ml erbB-2 (gift of Jim Huston, Creative Biomolecules), immobilized on 96 well microtiter plates by overnight incubation at 4°C. Plates were blocked for one hour at room temperature with 5%
FCS/PBS and fusion protein was allowed to bind for 4 hours. Detection was made possible by addition of CTLA-41g or anti-B7 mAb for 1 hour and then HRP conjugated anti-human or anti-mouse Ab, followed by incubation with peroxidase substrate and measurement at 405nm in an ELISA plate reader.
Measurement of Affinity and Binding Kinetics by SPR in a BlAcore
The Kd of purified chimeric fusion protein was determined using surface plasmon resonance in a BlAcore (Pharmacia Biosensor). All experiments were performed at 37°C
in HBSS buffer ((25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, and 0.005% surfactant P20)). In a BlAcore flow cell, approximately 1400 resonance units (RU) of 90kDa erbB-2 ECD (10ug/ml in 10mM sodium acetate pH 4.5) were coupled to a CM5 sensor chip using NHS-EDC chemistry 19. Association rates were measured under continuous flow of 15ul/minute using concentrations ranging from 5.0 x 10.8 to 8.0 to 10.7 M. ko, was determined from a plot of (ln(dR / dt))/t versus concentration. ko,,, was determined during from the dissociation part of the sensogram at the highest concentration of protein analyzed using a flow rate of 15ul/minute. Kd was calculated as koff, / kol.
Cell Surface Binding Assays for Fusion Protein
Cell surface binding of the fusion protein was performed by FACS analysis on a 
RESULTS
Construction of the Human B7.2/Anti-erbB-2 Fusion Protein
A chimeric fusion protein was engineered containing both the extracellular domain 
Determination of Kinetics by Surface Plasmon Resonance
To determine whether the anti-erbB-2 scFv half of the fusion protein retained its affinity for immobilized antigen, kinetics were measured by surface plasmon resonance on a BlAcore. Briefly, erbB-2 ECD was immobilized on a CM5 sensor chip using NHS-EDC chemistry. Associations were measured under continuous flow of 15ul/minute using a range of concentrations from 800 nM to 50 nM. koo was determined from a plot of (ln(dR/dt))/t versus concentration. koff was determined during the first two minutes of dissociation of the scFv from erbB-2 ECD and Kd was calculated as koJtkon. The 
Ability of HB7.2/B1 Fusion Protein to Bind to Counter
Receptors as Determined by ELISA.
The ability of hB7.2/B11 to bind to both immobilized erbB-2 and to soluble anti-B 7 molecule was determined by ELISA. ErbB-2 ECD coated microtiter plates were incubated with either purified hB7.2/B 1 or B 1 scFv and binding detected with either CTLA-41g, hB7.2 mAb, hB7.1 mAb or control followed by HRP conjugated anti-human Fc mAb or anti-mouse Fc mAb. Absorbance was measured at 405nm on an ELISA plate reader. as was the addition of 10 ug/ml anti-hCD28 mAb. In all cases, 1 ng/ml PMA and I uM ionomycin were added to augment the signal. 
